Search Result

Results for "

MDM2-p53 interaction inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Autophagy (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (8) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (26)
By Research Areas:	Cancer (26)

Inhibitors & Agonists

Screening Libraries

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130684

MDM2-IN-1	MDM-2/p53	Cancer
MDM2-IN-1 (Compound 30) is a synthetic **MDM2-p53 interaction (MDM2)** inhibitor and contains the trans (D-)configuration .

HY-144105

NSC405640	MDM-2/p53	Cancer
NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

HY-12941

AM-7209	MDM-2/p53	Cancer
AM-7209 is a potent and selective *MDM2-p53* interaction inhibitor with a K_d of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC₅₀ of 1.6 nM. AM-7209 shows antitumor activities .

HY-161039

MDM2-p53-IN-18	MDM-2/p53	Cancer
MDM2-p53-IN-18 (Compd A-7b) is a *MDM2-p53* interaction inhibitor .

HY-150620

BI-0282	MDM-2/p53	Cancer
BI-0282 (Compound 1) is a potent *MDM2-p53* interaction inhibitor .

HY-161041

MDM2-p53-IN-20	MDM-2/p53	Cancer
MDM2-p53-IN-20 (Compd B-11j) is a synthetic *MDM2-p53* interaction inhibitor that play an important role in cancer .

HY-149988

UNP-6457	MDM-2/p53	Cancer
UNP-6457 is a potent active *MDM2-p53* interaction inhibitor with an IC₅₀ values of 8.9 nM .

HY-161040

MDM2-p53-IN-19	MDM-2/p53	Cancer
MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the *MDM2-p53* interaction with anticancer activity .

HY-18331

MI-219	MDM-2/p53	Cancer
MI-219 is an antagonist for *MDM2* with a K_i of 13.3 μM. MI-219 inhibits the *MDM2-p53* interaction, inhibits thus the proliferation of FSCCL cells, with an IC₅₀ of 2.5 μM .

HY-133760

MI-888	MDM-2/p53	Cancer
MI-888 is an orally active *MDM2* inhibitor with a K_i of 0.44 nM. MI-888 can inhibit the *MDM2-p53* interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .

HY-16634

MI-888 TFA	MDM-2/p53	Cancer
MI-888 (TFA) is an orally active *MDM2-p53* interaction inhibitor with a K_i of 0.44 nM. MI-888 (TFA) can achieve rapid, complete, and sustained tumor regression in a xenograft mouse model of cancer .

HY-17493

MI-773 4 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
MI-773 is a potent *MDM2-p53* protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (K_d=8.2 nM). MI-773 has antitumor activity .

HY-18986

SAR405838 2 Publications Verification MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-125858

MI-1061 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-125858A

MI-1061 TFA 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 TFA is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-122038

NU-8165	MDM-2/p53	Cancer
NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .

HY-133754

MI-1063	MDM-2/p53 Ligands for Target Protein for PROTAC	Cancer
MI-1063 is an inhibitor for DMD-2, that blocks the MDM2-p53 interaction, and activates the tumor suppressor function of p53. MI-1063 inhibits the growth of cancer cell RS4-11 and MV4-11 with IC₅₀ of 179 nM and 93 nM. MI-1063 can be used as target protein ligand in synthesis of PROTAC degrader MD-265 (HY-169327) .

HY-151171

MDM2/4-p53-IN-3	MDM-2/p53	Cancer
MDM2/4-p53-IN-3 is a *MDM2/4-p53* protein-protein interactions (PPIs) inhibitor (IC₅₀s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .

HY-18986S

SAR405838-d10 MI-77301-d₁₀	Isotope-Labeled Compounds	Cancer
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-163083

JN122	MDM-2/p53 Apoptosis	Cancer
JN122, a spiroindoline-containing molecule, is a MDM2 inhibitor. JN122 Inhibits MDM2/p53 protein–protein interaction and exerts robust in vivo antitumor efficacy. JN122 has antiproliferative activity in HCT-116 cells and HEK-293 cells with IC₅₀ values of 39.6 nM and 4.28μM, respectively. JN122 can promote activation of p53 and its target genes, inhibited cell cycle progression, and induced cell apoptosis .

HY-125858B

(S,R,S)-MI-1061	Drug-Linker Conjugates for ADC MDM-2/p53	Others
(S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-10029

Nutlin-3a Maximum Cited Publications 49 Publications Verification Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits *MDM2-p53*?interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53?wild-type ovarian carcinomas .

HY-10029A

(Rac)-Nutlin-3 (Rac)-Rebemadlin	MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme	Cancer
(Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). (Rac)-Nutlin-3 inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas .

HY-107466

WK298	MDM-2/p53	Cancer
WK298 is a potent inhibitor of the MDM2/MDMX-p53 interaction with good anti-tumor activity. WK298 can fully activate the p53 pathway by inhibiting the binding of MDM2 and MDMX to p53. The development of WK298 benefited from a deep understanding of the key elements of the p53-MDM2/MDMX interaction structure .

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-W340839

p53-MDM2-IN-1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-W340313

p53-MDM2-IN-4	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

Cat. No.	Product Name

HY-L109

Protein-protein Interaction Inhibitor Library	656 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 656 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Protein-protein Interaction Inhibitor Library

656 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 656 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

Cat. No.	Product Name	Chemical Structure

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.